# The company must be covered by at least 4 of these 5 ratings for the calculation to be performed.

*biotech · news · 2026-01-08 · MarketScreener*

## Key points

- The Trader super rating combines Global Valuation, 4-month EPS Revisions, and Visibility scores.
- The Investor super rating includes Fundamentals, Global Valuation, 1-year EPS Revisions, and Visibility scores.
- The Global composite rating averages Fundamentals, Valuation, Estimate Revisions, Consensus, and Visibility scores.
- Global and Quality ratings require coverage by a minimum number of component ratings for calculation.

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/bayer-partners-with-souffle-therapeutics-to-develop-sirna-therapy-for-rare-heart-disease-ce7e59dddb8df32c)

---

Canonical: https://newsio.io/n/e6c9c16a-b354-44bd-a144-5c38b9840040/the-company-must-be-covered-by-at-least-4-of-these-5-ratings-for-the-calculation
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works